Recent experience includes:
Advised Bicycle Therapeutics on a filing made under the UK's National Security and Investment Act 2021 ("NSIA") regime in connection with its collaboration agreements with each of Bayer and Novartis to discover and develop Bicycle radioconjugates for multiple oncology targets.
U.S. medical technology company
Advised a U.S.-headquartered medical technology company on a potential abuse of dominance claim against an upstream supplier and competitor of raw materials.
UK consumer healthcare company
Advised a UK-based consumer healthcare company on the competition law implications of trademark co-existence agreements.
UK pharmaceutical company
Advised a UK pharmaceutical company on the enforceability of a post-term non-compete clause in an exclusive distribution agreement.
US biotechnology company
Advised a US biotechnology company that develops vaccines to counter serious infectious diseases on the competition law aspects relating to a supply agreement with the European Commission resulting in potential foreclosure from the market.
Global pharmaceutical company
Advised a global biopharmaceutical company on all competition law aspects relating to its template distribution agreements.
UK biopharmaceutical group
Advised a UK research-driven, speciality biopharmaceutical group on general competition law compliance, including review of distribution and licensing arrangements from an antitrust perspective.
Advised a specialist oncologist pharmaceutical company on general competition compliance matters related to its entry into the European market (especially, parallel trade and territorial restrictions) as well as preparing its first ever antitrust policy and dawn raid guidelines.
Advised a U.S. healthcare company on the competition law risks resulting from the proposed acquisition of another healthcare provider in the UK, respectively two of the largest private providers of in-patient mental healthcare services in the UK; resulting in an extended Phase 1 Competition & Markets Authority merger review with significant divestments.
Advised HC-One, a leading provider of health and social care services in the UK, on the merger control aspects of its acquisition of a portfolio of care homes from Bupa and securing a Phase I clearance from the CMA.
Advised on various licensing agreements with competitors and non-competitors from an EU/UK competition law perspective.
Advised this. FTSE 250 specialist pharmaceutical company on a range of multi-jurisdictional merger control issues in respect of M&A transactions.